NORWELL, Mass. — The National Organization for Rare Disorders (NORD®) has officially announced a new request for applications aimed at the implementation and launch of two brand-new patient registries on its established NORD® IAMRARE® platform. This significant healthcare initiative is being made possible through funding provided by the Rare Disease Cures Accelerator–Data and Analytics Platform (RDCA-DAP®), a major collaborative agreement established with the Critical Path Institute and funded by the U.S. Food and Drug Administration (FDA).
The upcoming registry implementation project represents a vital step forward in the ongoing effort to capture robust, patient-reported data across various underserved rare disease communities. By leveraging the advanced infrastructure of the IAMRARE platform, selected rare disease organizations will receive critical support to build, launch, and maintain dedicated registries designed to collect vital medical and lived-experience data directly from patients and their families.
"This opportunity builds on NORD’s work supporting rare disease nonprofits," says Tracey Sikora, Vice President of Research and Clinical Programs at NORD. "Research studies led by rare disease communities are an important source of data, and insights from IAMRARE-hosted studies have contributed to the development of clinical outcome assessments, updates to treatment guidelines, and at least one FDA approval."
The impact of patient-powered registries on rare disease research cannot be overstated. For decades, the scattered and often misunderstood nature of rare conditions has posed monumental hurdles for researchers, clinicians, and regulatory bodies alike. Because individual patient populations are frequently small and geographically dispersed, gathering enough consistent data to understand natural disease progression or measure therapeutic effectiveness has traditionally been exceptionally difficult. Patient registries serve as a powerful solution to this challenge, directly empowering patients to share their health journeys, symptoms, treatment responses, and quality-of-life metrics in a structured, secure, and standardized environment.
Under the terms of the newly announced application cycle, successful applicants will begin working closely with NORD starting in April 2027. Together, they will navigate the intricate and essential process of creating and launching a tailored patient registry for their specific rare disease community. NORD’s comprehensive involvement includes building and hosting the registry website, as well as providing extensive training and guidance to registry sponsors.
Throughout the setup phase, sponsors will be supported as they establish a dedicated registry advisory board, develop a comprehensive study protocol, build and customize targeted surveys, and successfully navigate the often-complex Institutional Review Board (IRB) process. Additionally, sponsors will receive expert guidance on how to determine clear criteria for sharing the valuable data collected by the registry with external researchers, industry partners, and academic investigators looking to advance clinical studies.
Application Criteria and Important Deadlines
Organizations interested in seizing this unique opportunity must meet specific eligibility and application criteria established by NORD and its program partners. The application window is officially open, giving qualifying rare disease organizations time to prepare and submit their comprehensive proposals before the final submission deadline.
The request for applications will officially close on January 10, 2027. Following the close of the submission period, NORD will review the proposals, and accepted applicants will be formally notified by February 1, 2027. Following notification and preliminary coordination, the actual implementation of the two new patient registries is scheduled to officially kick off in April 2027.
Organizations seeking to apply can access the submission portal directly through NORD’s online application link. Furthermore, any prospective applicants who have specific inquiries or require technical clarification regarding the request for applications are encouraged to reach out to NORD’s designated administrative team via email for prompt assistance.
About the NORD® IAMRARE® Platform
The expansion of the IAMRARE platform marks another milestone for NORD’s digital infrastructure. Currently, NORD’s IAMRARE Platform proudly hosts more than 55 live registries that are actively sponsored and managed by individual patient advocacy organizations. The primary purpose of these registries is to systematically collect, curate, and utilize patient-reported data to drive scientific discovery, medical understanding, and therapeutic development. By putting the power of data collection directly into the hands of the communities most affected by these conditions, IAMRARE continues to bridge the gap between patients and researchers.
About the Rare Disease Cures Accelerator–Data and Analytics Platform (RDCA-DAP®)
The funding that makes this current registry expansion possible originates from the Rare Disease Cures Accelerator–Data and Analytics Platform (RDCA-DAP®). RDCA-DAP is an innovative, FDA-sponsored initiative engineered to provide a centralized, highly standardized technological infrastructure. Its core mission is to support and dramatically accelerate rare disease characterization, with the ultimate goal of expediting the development and approval of much-needed therapies for patients who have historically lacked viable treatment options.
About the National Organization for Rare Disorders (NORD®)
Founded in 1983, the National Organization for Rare Disorders (NORD®) stands as a leading independent, nonpartisan nonprofit organization dedicated entirely to improving the health, well-being, and daily lives of the more than 30 million Americans currently affected by rare diseases.
NORD achieves its sweeping mission through robust partnerships with more than 350 disease-specific member patient organizations. Its national footprint also includes 49 designated NORD Rare Disease Centers of Excellence, which collectively span more than 170 academic medical centers, major research institutions, and prominent children’s hospitals nationwide. Through these collaborative networks, NORD consistently advances expert medical care, pioneering research, public education, and aggressive advocacy to forge a brighter, more hopeful future for every individual and family impacted by a rare condition.
